Common misconceptions

Common mistake
Wrong: Alopecia areata causes diffuse thinning in a frontoparietal pattern similar to androgenetic alopecia.
Right: Alopecia areata causes discrete, well-circumscribed patches of non-scarring hair loss, often with exclamation-point hairs at the margins.
Alopecia areata is an autoimmune condition where T cells attack hair follicles, producing sharply demarcated, patchy bald spots — not a gradual frontoparietal recession. The signature finding is exclamation-point hairs (tapered at the base, wider distally) at the patch margins. Androgenetic alopecia, by contrast, is DHT-driven follicular miniaturization that follows a predictable pattern (temples and vertex in men; crown thinning in women) with no discrete patches.
Common mistake
Wrong: Finasteride treats androgenetic alopecia by blocking androgen receptors.
Right: Finasteride inhibits 5-alpha reductase, reducing conversion of testosterone to DHT, which is the primary driver of follicular miniaturization.
Finasteride does not block androgen receptors — that's the mechanism of drugs like spironolactone or flutamide. Finasteride inhibits 5-alpha reductase (specifically type II), the enzyme that converts testosterone to dihydrotestosterone (DHT). DHT binds follicle androgen receptors with much higher affinity than testosterone, driving miniaturization; reducing DHT production is what slows hair loss. This distinction matters because the exam can ask about mechanism, side effects (gynecomastia, sexual dysfunction), or which enzyme is targeted.
Common mistake
Wrong: Telogen effluvium hair loss occurs immediately after the triggering stressor.
Right: Telogen effluvium presents 2–3 months after the triggering event (surgery, illness, childbirth) because follicles must complete the telogen phase before shedding.
The delay exists because hair follicles have a biological clock — after a stressor (major surgery, severe illness, postpartum), follicles are prematurely pushed into telogen (resting phase), but they don't shed until the telogen phase completes, which takes roughly 2–3 months. This means the patient presents with diffuse shedding well after they've recovered from the original event, which often makes the connection non-obvious. The key clinical clue is diffuse loss (not patchy, not patterned) in a patient with a significant physiologic stressor 2–3 months prior.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Given a clinical description of hair loss, identify whether the pattern, distribution, and scalp appearance point to alopecia areata, androgenetic alopecia, telogen effluvium, or scarring alopecia.
  2. Given a patient on finasteride or minoxidil, explain or identify the mechanism of action that makes each drug effective in androgenetic alopecia.

Can you avoid these mistakes?

A 28-year-old woman presents with several coin-sized, smooth bald patches on her scalp. Dermoscopy shows short hairs that are wider at the tip than at the scalp end. What is the diagnosis, and what is the first-line treatment?
A man is prescribed finasteride for hair loss. His friend asks how it works. He says 'it blocks the receptor that DHT binds to on the hair follicle.' What is wrong with this explanation, and what is the correct mechanism?
A 32-year-old woman delivered a healthy baby 10 weeks ago and now notices dramatic diffuse hair shedding. Her scalp appears normal without erythema or scarring. What is the diagnosis, and what is the expected prognosis?
A 45-year-old man has progressive thinning at the temples and crown but a preserved occipital hairline. A 55-year-old woman has diffuse thinning over the crown with a preserved frontal hairline. What unifies these two presentations mechanistically, and how does the treatment differ by sex?

Related topics

See how your Anki deck covers this topic.

Upload your deck for a free audit →